Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifeTech ScientificLFTSF 95 EV-to-EBITDA is 21.26 as of Jul. 31, 2026, which is 20% below its 10-year median of 26.69. GuruFocus rates LFTSF with a GF Score™ of 95/100 and a GF Value™ of $0.34. The stock has 4 warning signs investors should review. Among 510 Medical Devices & Instruments companies, LifeTech Scientific ranks worse than 71.96% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LifeTech Scientific's enterprise value is $611.5 Mil.
LifeTech Scientific's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $28.8 Mil. Therefore, LifeTech Scientific's EV-to-EBITDA for today is 21.26.
The historical rank and industry rank for LifeTech Scientific's EV-to-EBITDA or its related term are showing as below:
LFTSF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 14.1 Med: 26.69 Max: 136.66
Current: 21.42
During the past 13 years, the highest EV-to-EBITDA of LifeTech Scientific was 136.66. The lowest was 14.10. And the median was 26.69.
LFTSF's EV-to-EBITDA is ranked worse than 71.96% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.415
vs LFTSF: 21.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LifeTech Scientific's PE Ratio (TTM) for today is calculated as:
LifeTech Scientific's share price for today is $0.2335.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LifeTech Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for LifeTech Scientific's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LifeTech Scientific's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's EV-to-EBITDA falls into.
LifeTech Scientific's current Enterprise Value is $611.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LifeTech Scientific's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $28.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeTech Scientific (LFTSF) has a EV-to-EBITDA of 21.26 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LifeTech Scientific. This is 20% below median its historical median of 26.69. Over the past decade, LifeTech Scientific's EV-to-EBITDA has ranged from 14.10 to 136.66. According to the industry distribution chart, LifeTech Scientific ranks #367 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 72%.
Is LifeTech Scientific's EV-to-EBITDA too high?
LifeTech Scientific's current EV-to-EBITDA of 21.26 is 20% below median its 10-year median of 26.69. Over the past 10 years, this metric has ranged from a low of 14.10 to a high of 136.66. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.42. LifeTech Scientific's value of 21.26 is 47.5% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #367 out of 510 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LifeTech Scientific has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #367 out of 510 companies for EV-to-EBITDA. This places LifeTech Scientific in the lower half of its industry. The industry median EV-to-EBITDA is 14.42. LifeTech Scientific's value of 21.26 is 47.5% above this benchmark. Historically, LifeTech Scientific's own EV-to-EBITDA has ranged from 14.10 to 136.66 over the past decade. While the company's 10-year median is 26.69 vs. the industry median of 14.42, LifeTech Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.42, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current EV-to-EBITDA of 21.26 is 47.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LifeTech Scientific. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current EV-to-EBITDA is 21.26, which is 20% below median its own 10-year median of 26.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (LFTSF) has a current EV-to-EBITDA of 21.26. The stock's GF Value™ is $0.34, compared to a current price of $0.23 — trading 31.3% below its estimated fair value. The current EV-to-EBITDA is 21.26, which is 20% below median its 10-year median of 26.69 and 47.5% above the Medical Devices & Instruments industry median of 14.42. LifeTech Scientific's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For LifeTech Scientific (LFTSF), the current EV-to-EBITDA is 21.26 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (LFTSF) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of $0.23 is trading 31.3% below its estimated GF Value™ of $0.34.
Key valuation signals for LFTSF:
EV-to-EBITDA: 21.26 (20% below median its 10-year median of 26.69)
GF Value™: $0.34 vs. price of $0.23 (31.3% below fair value)
Industry Position: 47.5% above the Medical Devices & Instruments median (#367 of 510)
No single metric tells the full story. See the LFTSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
95GF Score
Get the complete analysis for LFTSF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFTSF has been successfully added to your 
